Charting progress in genetic medicine: Norstella highlights industry momentum at ASGCT

Published on July 1, 2025

At the 28th annual American Society of Gene & Cell Therapy (ASGCT) conference in New Orleans, ASGCT’s CEO David Barrett and Citeline’s Dan DiGaudio, Senior Associate, Consulting and Analytics, shared key findings from the most recent Cell and Gene Therapy Quarterly Landscape Report—a collaborative effort between ASGCT and Citeline, a Norstella company. Their presentation not […]

Continue reading on website
Other news

Xtalks Spotlight: How can potency assays ensure more successful clinical & commercial outcomes?

June 30, 2025
Potency assays play a vital role in biopharmaceutical development by measuring a drug candidate’s biological activity against a reference standard — offering essential insights into product quality and its potential clinical success.From early research through commercial release, the development and validation of these assays help confirm a therapy’s functional performance and batch-to-batch consi

BioPharm International: At BIO 2025, As Political Shifts Continue, Key Leaders Respond

July 1, 2025
In this recent article with BioPharm International, Matthew Stober, CEO, joins peers from FUJIFILM, Tevard, Junevity, and Mabion to discuss how FDA turnover, the BIOSECURE Act, potential tariffs, and shifting federal R&D funding streams are influencing strategy.Pharmaceutical Technology® Group was able to interview more than a half dozen executives in the biopharmaceutical industry as part of its